SCHEMBL29660836

SCHEMBL29660836

OC1(c2ccc(Br)cc2)CC(OCc2ccccc2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.43
OPRL1 P41146 4/20 0.43
DPP4 P27487 1/20 0.43
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40
OPRD1 P41143 3/20 0.40
OPRK1 P41145 3/20 0.40
EPHX2 P34913 2/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
ACE2 Q9BYF1 1/20 0.38
KDM1A O60341 1/20 0.38
RCOR1 Q9UKL0 1/20 0.38
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
SLC6A4 P31645 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20284995 0.89 OPRL1 (0.51) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL23714847 0.85 MAOB (0.43) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL25317048 0.84 LMNA (0.50) EPHX2
SCHEMBL22815877 0.80 CARM1 (0.42) OPRM1OPRL1DPP4EPHX2KDM1A
SCHEMBL26775766 0.77 CTSL (0.49) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL25554036 0.77 OPRM1 (0.41) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL30116853 0.75 KDM1A (0.38) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL24105723 0.75 KDM1A (0.38) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL1583843 0.75 OPRM1 (0.37) OPRM1OPRL1DPP4CTSLCTSB
SCHEMBL16975554 0.74 OPRM1 (0.49) OPRM1OPRL1DPP4CTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528802-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-20 US disclosed
US-20220274982-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-01 US disclosed
EP-4005638-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528802-B2 Heterocyclic compound GBA2, GBA1, GALC OPRM1 2430/4885OPRL1 2687/4885DPP4 3300/4885
US-20220274982-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC OPRM1 4786/4885OPRL1 4037/4885DPP4 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.